PR Newswire
LEXINGTON, Mass., Sept. 11, 2017
LEXINGTON, Mass., Sept. 11, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:
ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other
diseases related to endogenous aldehyde toxicity, today announced it will hold a webcast and conference call on Tuesday, September 12, 2017 at 8:00 a.m. EDT to provide the results from its dry
eye disease Phase 2a clinical trial.
The dial-in numbers are 1-877-870-4263 for domestic callers and 1-412-317-0790 for international callers. A live webcast
of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website
at www.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website
for one year.
About Aldeyra Therapeutics
Aldeyra Therapeutics,
Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat
diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic
molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development as topical eye drops for the
treatment of ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical trials in dry eye disease,
allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic form of ADX-102 is in late-stage clinical development
for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an inborn error of aldehyde metabolism. ADX-102 has not been
approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original content with multimedia:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-announce-results-from-dry-eye-disease-phase-2a-clinical-trial-300517028.html
SOURCE Aldeyra Therapeutics, Inc.